Marshall Wace LLP boosted its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 4,510.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 783,988 shares of the medical research company's stock after buying an additional 766,983 shares during the quarter. Marshall Wace LLP owned 0.52% of Bruker worth $45,957,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FIL Ltd lifted its position in Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after acquiring an additional 1,420,102 shares during the last quarter. Norges Bank purchased a new stake in Bruker in the 4th quarter valued at $63,378,000. Vaughan Nelson Investment Management L.P. grew its position in Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after purchasing an additional 666,617 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Bruker by 139.3% in the fourth quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company's stock valued at $30,844,000 after purchasing an additional 306,282 shares during the period. Finally, Ceredex Value Advisors LLC acquired a new stake in shares of Bruker during the fourth quarter worth about $14,344,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.
Bruker Trading Up 3.5 %
NASDAQ:BRKR traded up $1.29 during trading hours on Wednesday, reaching $38.25. 772,140 shares of the company were exchanged, compared to its average volume of 1,503,571. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The stock has a 50 day simple moving average of $43.92 and a 200 day simple moving average of $53.25. Bruker Co. has a 52-week low of $34.10 and a 52-week high of $83.32.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, analysts predict that Bruker Co. will post 2.69 EPS for the current year.
Bruker Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.52%. The ex-dividend date was Monday, March 17th. Bruker's payout ratio is currently 26.32%.
Analyst Ratings Changes
Several research firms have recently commented on BRKR. Citigroup reduced their target price on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Barclays lowered their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Stifel Nicolaus lowered their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Finally, Wells Fargo & Company reduced their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Bruker presently has an average rating of "Moderate Buy" and a consensus target price of $65.00.
Check Out Our Latest Analysis on Bruker
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
